Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012 Jul 19; 120(3):552-9.

View in: PubMed

collapse authors with profiles